Evidence map›Paper›PMID 38194790›Full record

ArticleJournal of autoimmunity2024

Proximity extension assay proteomics and renal single cell transcriptomics uncover novel urinary biomarkers for active lupus nephritis.

Yaxi Li, Chenling Tang, Kamala Vanarsa, Nga Thai, Jessica Castillo, Gabrielle Alexis Braza Lea, Kyung Hyun Lee, Soojin Kim, Claudia Pedroza, Tianfu Wu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of autoimmunity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Lipocalin-2 and intestinal diseases.World journal of gastroenterology · 2024
    Review
  11. Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Yaxi LiDepartment of Biomedical Engineering, University of Houston, Houston, TX, USA.
Chenling TangDepartment of Biomedical Engineering, University of Houston, Houston, TX, USA.
Kamala VanarsaDepartment of Biomedical Engineering, University of Houston, Houston, TX, USA.
Nga ThaiDepartment of Biomedical Engineering, University of Houston, Houston, TX, USA.
Jessica CastilloDepartment of Biomedical Engineering, University of Houston, Houston, TX, USA.
Gabrielle Alexis Braza LeaDepartment of Biomedical Engineering, University of Houston, Houston, TX, USA.
Kyung Hyun LeeCenter for Clinical Research and Evidence-Based Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA.
Soojin KimDepartment of Biomedical Engineering, University of Houston, Houston, TX, USA.
Claudia PedrozaCenter for Clinical Research and Evidence-Based Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA.
Tianfu WuDepartment of Biomedical Engineering, University of Houston, Houston, TX, USA.
Ramesh SaxenaDepartment of Internal Medicine, Division of Nephrology, UT Southwestern Medical Center, Dallas, TX, USA.
Chi Chiu MokDepartment of Medicine, Tuen Mun Hospital, New Territories, Hong Kong, China.
Chandra MohanDepartment of Biomedical Engineering, University of Houston, Houston, TX, USA. Electronic address: cmohan@central.uh.edu.
University of Houston · USCenter for Clinical Research (United States) · USSouthwestern Medical Center · USTuen Mun Hospital · CN

Funding

Monitoring Disease in LupusR01AR074096 · NIAMS · UNIVERSITY OF HOUSTON · PI CHANDRA MOHAN · 2019 to 2026
$4.5M
Objective Classification of Lupus NephritisR01DK134055 · NIDDK · UNIVERSITY OF HOUSTON · PI CHANDRA MOHAN, Hien Van Nguyen · 2023 to 2026
$2.5M
A biomarker panel based smart mini-array system for the homecare of autoimmune kidney diseasesR01AG062987 · NIA · UNIVERSITY OF HOUSTON · PI WU, TIANFU · 2019 to 2023
$2.2M
NIAMS NIH HHS R01 AR074096NIA NIH HHS R01 AG062987NIDDK NIH HHS R01 DK134055
6 · The paper itself

Abstract

objectiveTo identify urinary biomarkers that can distinguish active renal involvement in Lupus Nephritis (LN), a severe manifestation of systemic lupus erythematosus (SLE).

methodsUrine from 117 subjects, comprised of inactive SLE, active non-renal lupus, active LN, and healthy controls, were subjected to Proximity Extension Assay (PEA) based comprehensive proteomics followed by ELISA validation in an independent, ethnically diverse cohort. Proteomic data is also cross-referenced to renal transcriptomic data to elucidate cellular origins of biomarkers.

resultsSystems biology analyses revealed progressive activation of cytokine signaling, chemokine activity and coagulation pathways, with worsening renal disease. In addition to validating 30 previously reported biomarkers, this study uncovers several novel candidates. Following ELISA validation in an independent cohort of different ethnicity, the six most discriminatory biomarkers for active LN were urinary ICAM-2, FABP4, FASLG, IGFBP-2, SELE and TNFSF13B/BAFF, with ROC AUC ≥80%, with most correlating strongly with clinical disease activity. Transcriptomic analyses of LN kidneys mapped the likely origin of these proteins to intra-renal myeloid cells (CXCL16, IL-1RT2, TNFSF13B/BAFF), T/NK cells (FASLG), leukocytes (ICAM2) and endothelial cells (SELE).

conclusionIn addition to confirming the diagnostic potential of urine ALCAM, CD163, MCP1, SELL, ICAM1, VCAM1, NGAL and TWEAK for active LN, this study adds urine ICAM-2, FABP4, FASLG, IGFBP-2, SELE, and TNFSF13B/BAFF as additional markers that warrant systematic validation in larger cross-sectional and longitudinal cohorts.

Indexed as

Lupus Erythematosus, SystemicLupus NephritisBiomarkersCross-Sectional StudiesEndothelial CellsGene Expression ProfilingHumansInsulin-Like Growth Factor Binding Protein 2KidneyProteomicsBiomarkersInsulin-Like Growth Factor Binding Protein 2BiomarkerLupus nephritisProximity extension assayTranscriptomics

Identifiers

PMID38194790
PMCPMC13682863
OpenAlexW4390683361

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.